ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 597

Comparative Effectiveness of Different Anti-TNF Drugs As First Biological DMARD in RA: Results from the Nationwide Swedish Register 2010-2015

Thomas Frisell1, Mats Dehlin2, Daniela Di Giuseppe3, Nils Feltelius4, Alf Kastbom5, Carl Turesson6, Johan Askling7 and the ARTIS Study Group, 1Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 3Clinical Epidemiology Unit, Dept. of Medicine, K2, Karolinska institutet, Stockholm, Sweden, 4Swedish Medical Products Agency, Uppsala, Sweden, 5Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, 6Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, 7Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: anti-TNF therapy, outcomes, rheumatoid arthritis (RA) and treatment options

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 13, 2016

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Although evidence from randomized trials suggest similar efficacy and safety on a group level for the different anti-TNF drugs available for the treatment of RA, and many treatment guidelines rank them as interchangeable in terms of effect, there are few head-to-head comparisons and limited real world data on their comparative effectiveness in clinical practice. Our objective was therefore to perform a head-to-head comparison of the initial effectiveness of different TNF inhibitors among bionaïve patients with RA in a large population-representative sample

Methods: The Swedish Rheumatology Register (SRQ) covers about 95% of all biological treatment of RA, with data on clinical characteristics prospectively recorded at treatment initiation and at subsequent patient visits. We included all patients with RA registered in the SRQ as starting etanercept, infliximab (including originator product and its biosimilar), adalimumab, certolizumab pegol, or golimumab as their first ever biological DMARD (N=6149) between 1st Jan 2010 and 31st July 2015, with follow-up through March 31st2016. Effectiveness was defined as 1) remaining on therapy, 2) being in remission or low disease activity (DAS28<2.6), and 3) having achieved a EULAR response, all at the evaluation visit at 5 (3-8) months after start (defined as the visit closest to 151 days of all visits between 60 and 242 days; this method has previously been shown to capture 95% of patients with follow-up visits within one year of treatment initiation). Differences in crude proportions were tested across drugs using χ2-tests. To take baseline differences in patient characteristics into account, relative risks were estimated using generalized log-binomial regression adjusting for sex, age, concomitant use of DMARDs, Rheumatoid Factor, HAQ, and disease duration.

Results: : Across all anti-TNF drugs, about 90% remained on therapy until the evaluation visit, and most patients remaining on drug also had a positive response, with about 40% having DAS28 below 2.6, and almost half reaching a good EULAR response. As shown in the Table, only the crude proportion with DAS28 below 2.6 was statistically significantly different across treatments (p=0.011), but this difference was no longer significant after taking baseline characteristics, and proportions discontinuing drug, into account. Although some one-on-one comparisons approached borderline significance (e.g. lower proportion discontinuing therapy in adalimumab vs.etanercept, p=0.06), the number of pairwise tests lead to risk of false positives, and the global test showed no significant inter-drug difference.

Conclusion:  These results suggest limited differences in effectiveness among available TNF inhibitors for the treatment of RA in current clinical practice, at least regarding the initial response among previously bionaïve patients

Status at evaluation visit at 5 months among all patients with RA initiating TNFi as first ever biologic DMARD 2010-2015 in Sweden

Etanercept

Infliximab

Adalimumab

Certolizumab pegol

Golimumab

P-value

N

1826

1495

1087

979

762

Observed percentage
Discontinued

11.5

9.8

9.2

11.6

9.2

0.11

DAS28 < 2.6*

42.9

35.9

42.2

39.1

41.9

0.01

EULAR response*
Good

47.3

42.0

46.8

46.0

46.0

0.23

Moderate

29.2

32.8

30.3

31.6

30.5

0.58

None

23.5

25.2

22.9

22.4

23.6

0.79

Adjusted relative risk†
Discontinued

Ref.

0.89 (0.71-1.13)

0.77 (0.59-1.01)

1.01 (0.80-1.29)

0.83 (0.62-1.12)

0.25

DAS28 < 2.6‡

Ref.

0.92 (0.81-1.04)

1.03 (0.91-1.16)

0.95 (0.83-1.09)

0.99 (0.85-1.14)

0.54

EULAR response¶
Good

Ref.

0.94 (0.83-1.06)

1.01 (0.88-1.15)

1.05 (0.92-1.20)

1.03 (0.89-1.20)

0.57

Good or Moderate

Ref.

0.99 (0.91-1.07)

1.02 (0.93-1.12)

1.06 (0.97-1.15)

1.05 (0.95-1.15)

0.59

None or discontinued

Ref.

1.07 (0.93-1.23)

0.93 (0.80-1.09)

1.08 (0.93-1.26)

0.95 (0.80-1.14)

0.32

Notes: P-values from χ2-tests for proportions, and type 3 Wald test in regression model, *) Proportion among those remaining on drug.
†) Adjusted for sex, age, RF, baseline disease duration, HAQ, and concomitant use of MTX, non-MTX DMARD, corticosteroids
‡) Comparing “remission” to “no-remission, or no longer on therapy”
¶) Comparing each response category to “any other response, or no longer on therapy”

.


Disclosure: T. Frisell, None; M. Dehlin, None; D. Di Giuseppe, None; N. Feltelius, None; A. Kastbom, BMS, Roche, UCB, 5; C. Turesson, Abbvie, BMS, Novartis, Pfizer, 5,Abbvie, Pfizer, Roche, 2; J. Askling, UCB, Roche, Merck, Pfizer, and Abbvie, 2.

To cite this abstract in AMA style:

Frisell T, Dehlin M, Di Giuseppe D, Feltelius N, Kastbom A, Turesson C, Askling J. Comparative Effectiveness of Different Anti-TNF Drugs As First Biological DMARD in RA: Results from the Nationwide Swedish Register 2010-2015 [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/comparative-effectiveness-of-different-anti-tnf-drugs-as-first-biological-dmard-in-ra-results-from-the-nationwide-swedish-register-2010-2015/. Accessed January 25, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-effectiveness-of-different-anti-tnf-drugs-as-first-biological-dmard-in-ra-results-from-the-nationwide-swedish-register-2010-2015/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.